Scarica l'app Stockscreener
39.85
5.99%
-2.54
Dopo l'orario di chiusura:
39.85
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché AKRO Giù?
Forum
Previsione
Precedente Chiudi:
$42.39
Aprire:
$42.39
Volume 24 ore:
1.33M
Relative Volume:
1.25
Capitalizzazione di mercato:
$3.58B
Reddito:
-
Utile/perdita netta:
$-237.22M
Rapporto P/E:
-10.54
EPS:
-3.78
Flusso di cassa netto:
$-212.64M
1 W Prestazione:
-11.19%
1M Prestazione:
+6.66%
6M Prestazione:
+15.67%
1 anno Prestazione:
+91.59%
Intervallo 1D:
$39.66
$44.81
Intervallo di 1 settimana:
$39.66
$45.24
Portata 52W:
$17.86
$58.40
Akero Therapeutics Inc Stock (AKRO) Company Profile
Nome
Akero Therapeutics Inc
Settore
Industria
Telefono
650-487-6488
Indirizzo
601 GATEWAY BOULEVARD, SUITE 350, SOUTH SAN FRANCISCO, CA
Confronta AKRO con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AKRO
Akero Therapeutics Inc
|
39.85 | 3.58B | 0 | -237.22M | -212.64M | -3.78 |
|
VRTX
Vertex Pharmaceuticals Inc
|
424.99 | 128.84B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
527.78 | 65.38B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
549.65 | 39.67B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.15 | 33.82B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
231.99 | 27.60B | 3.81B | -644.79M | -669.77M | -6.24 |
Akero Therapeutics Inc Stock (AKRO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-01-30 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2025-01-27 | Reiterato | H.C. Wainwright | Buy |
| 2024-11-18 | Iniziato | Citigroup | Buy |
| 2024-04-22 | Ripresa | BofA Securities | Neutral |
| 2023-09-19 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-08-28 | Iniziato | UBS | Buy |
| 2023-01-27 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2022-09-14 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2021-10-19 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-10 | Iniziato | BofA Securities | Buy |
| 2021-02-26 | Iniziato | Guggenheim | Buy |
| 2020-09-10 | Iniziato | Morgan Stanley | Overweight |
| 2020-07-20 | Reiterato | H.C. Wainwright | Buy |
| 2020-07-07 | Iniziato | Chardan Capital Markets | Buy |
| 2020-07-01 | Reiterato | H.C. Wainwright | Buy |
| 2020-03-02 | Iniziato | H.C. Wainwright | Buy |
| 2020-02-10 | Iniziato | Canaccord Genuity | Buy |
| 2019-07-15 | Iniziato | Evercore ISI | Outperform |
| 2019-07-15 | Iniziato | JP Morgan | Overweight |
| 2019-07-15 | Iniziato | Jefferies | Buy |
| 2019-07-15 | Iniziato | ROTH Capital | Buy |
Mostra tutto
Akero Therapeutics Inc Borsa (AKRO) Ultime notizie
8,390 Shares in Akero Therapeutics, Inc. (NASDAQ:AKRO) Acquired by Susquehanna Fundamental Investments LLC - MarketBeat
Akero Therapeutics Reports Positive Trial Data for Prospective Cirrhosis Drug - marketscreener.com
Deep Track Capital LP Purchases 800,216 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat
Akero reports promising cirrhosis treatment trial results - Investing.com
Akero Therapeutics Presents Week 96 Results from Phase 2b - GlobeNewswire
Akero Therapeutics Announces Publication of Phase 2b SYMMETRY Trial in the New England Journal of Medicine - GlobeNewswire
Akero Therapeutics Presents Phase 2b SYMMETRY Trial Results Significant for Efruxifermin in Treating Fibrosis in Compensated Cirrhosis Due to MASH at EASL Congress 2025 - Nasdaq
Akero Therapeutics Presents Week 96 Results from Phase 2b SYMMETRY Clinical Trial of Efruxifermin in Patients with Compensated Cirrhosis Caused by MASH Showing Fibrosis Improvement without Worsening of MASH at the EASL Congress 2025 - Stock Titan
Renaissance Technologies LLC Invests $579,000 in Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat
Alkeon Capital Management LLC Trims Stock Holdings in Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Encourages Akero Therapeutics, Inc. (AKRO) Investors to Inquire about Securities Investigation - ACCESS Newswire
Cutter Capital Management LP Invests $6.40 Million in Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat
Aquatic Capital Management LLC Increases Stock Position in Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat
Schonfeld Strategic Advisors LLC Sells 16,028 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat
5AM Venture Management LLC Invests $4.59 Million in Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat
Akero Therapeutics to Present at BofA Securities 2025 Health Care Conference - Nasdaq
Akero Therapeutics to Present at the BofA Securities 2025 Healthcare Conference - Stock Titan
Akero Therapeutics Inc expected to post a loss of 97 cents a shareEarnings Preview - TradingView
No Stopping Akero Therapeutics Inc (NASDAQ: AKRO)’s Stock Plunged? - Stocksregister
Akero Therapeutics, Inc. (NASDAQ:AKRO) Stock Holdings Decreased by Envestnet Asset Management Inc. - Defense World
Akero Therapeutics (AKRO) to Release Earnings on Friday - MarketBeat
Tower Research Capital LLC TRC Has $450,000 Stock Position in Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat
Pharma Co. Escapes Investor Liver Drug Trial Suit, For Now - Law360
Akero Beats Investor Suit Over Liver Drug Trial Design for Now - Bloomberg Law News
Akero Therapeutics, Inc. (NASDAQ:AKRO) Receives $76.29 Consensus Target Price from Brokerages - MarketBeat
Long-Term Shareholders Have Rights – If You Hold Akero - GlobeNewswire
Long-Term Shareholders Have Rights – If You Hold Akero Therapeutics, Inc. (NASDAQ: AKRO); ... - Bluefield Daily Telegraph
Long-Term Shareholders Have Rights – If You Hold Akero Therapeutics, Inc. (NASDAQ: AKRO); Integra Lifesciences Holdings Corporation (NASDAQ: IART); Mercury Systems, Inc. (NASDAQ: MRCY); or Virtu Financial Inc. (NASDAQ: VIRT), Contact Grabar La - TradingView
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Akero Therapeutics, Inc. (AKRO) And Encourages Shareholders to Reach Out - ACCESS Newswire
Emerald Mutual Fund Advisers Trust Trims Stake in Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat
Invesco Ltd. Purchases 21,086 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat
T. Rowe Price Investment Management Inc. Decreases Holdings in Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat
Foresite Capital Management VI LLC Makes New $10.15 Million Investment in Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat
Akero Therapeutics, Inc. (NASDAQ:AKRO) Insider Sells $256,437.50 in Stock - MarketBeat
Akero Therapeutics, Inc. (NASDAQ:AKRO) Shares Purchased by Price T Rowe Associates Inc. MD - MarketBeat
Brokerages Set Akero Therapeutics, Inc. (NASDAQ:AKRO) Target Price at $76.29 - Defense World
Akero Therapeutics (AKRO) Projected to Post Quarterly Earnings on Friday - Defense World
Dark Forest Capital Management LP Buys Shares of 16,893 Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat
Wells Fargo & Company MN Acquires 7,587 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat
Press Release Distribution & PR Platform - ACCESS Newswire
How does Akero Therapeutics Inc (AKRO) change from a tortoise to a hare? - Sete News
AKRO’s 2023 Market Dance: Up 63.95% – Time to Invest? - investchronicle.com
Akero Therapeutics (AKRO) Receives Buy Rating with Promising Pot - GuruFocus
Akero Therapeutics Inc (AKRO) receives a Buy rating from BofA Securities - knoxdaily.com
Jump Financial LLC Decreases Stake in Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat
Akero (AKRO) Among Leading FGF21 Developers, Says Cantor Fitzgerald | AKRO Stock News - GuruFocus
Do investors need to be concerned about Akero Therapeutics Inc (AKRO)? - uspostnews.com
Akero Therapeutics Inc Azioni (AKRO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.84%
0.15%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):